Brandl Talos advises biotech start-up Sarcura on EUR 2.5 million seed financing round

• Venture Capital & Start Ups from Adrian Zuschmann, Markus Arzt

Vienna, November 19, 2020 – Sarcura GmbH, a Vienna-based biotech start-up, secures €2.5 million in its seed funding round from renowned venture capital investors including IST Cube, Nina Capital and Axilium Capital.

Sarcura is working on the development of an innovative manufacturing platform for autologous cell therapy. The interdisciplinary founding team combines microfluidics and microchip technology to revolutionize the industrial manufacturing of personalized cell therapy. In doing so, the company aims to fully automate the manufacturing of highly potent, live drugs through real-time process and inline quality control at the cellular level. Sarcura will use the investment to advance the development of its first product, a GMP cell sorter.

The Brandl & Talos transaction team consisted of Markus Arzt and Adrian Zuschmann.

» We are very pleased that Sarcura trusted our expertise in their seed financing round. The start-up has a promising founding team and aims to make a significant contribution to the industrial production of personalized cell therapy. We hope that Sarcura will be able to successfully launch their venture through the investment. «

Markus Arzt

The team

Adrian Zuschmann

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 17
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 11
            [filter] => raw
        )

)

Partner / Corporate Law & Transactions, Venture Capital & Start Ups

Adrian specializes in corporate transactions, advising institutional and strategic investors, founders, and growth companies.
His practice centers on navigating clients through complex financing rounds, M&A and private equity transactions, portfolio investments, and exit strategies.

JUVE Verlag has recognized Adrian as a "rising star" in M&A for two consecutive years and included him in its inaugural "14 under 40" ranking for Austria.

Queen Mary University of London (MSc Law & Finance 2020)
University of Vienna, Faculty of Law (Magister iuris 2015)

Markus Arzt

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 17
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 11
            [filter] => raw
        )

)

Partner / Fund Formation, Capital Markets, Venture Capital & Start Ups, Corporate Law & Transactions

In recent years, Markus has spearheaded various large international transactions and is a respected venture capital and private equity expert.

University of Vienna, Faculty of Law (Mag. iur. 2012)

Latest insights into
Venture Capital & Start Ups

BRANDL TALOS advises Graph Therapeutics on USD 3.1 million pre-seed financing round

Press release • Venture Capital & Start Ups from Stephan Strass, Lara Präthaler

Graph Therapeutics, a next-generation techbio company, has successfully closed a USD 3.1 million pre-seed financing round. The round is led by Squareone and Merantix Capital, with participation from NAVEC Investment Management and strategic angel investors such as the Atomico Angel Program.

BRANDL TALOS advised Springtime and its Founders on growth equity investment from Scottish Equity Partners

Press release • Venture Capital & Start Ups from Roman Rericha, Adrian Zuschmann, Joseph Gstöttner, Daniel Habich

Springtime Technologies, a leading provider of AI-driven accounts payable automation software, has received a significant growth equity investment from Scottish Equity Partners (SEP), one of Europe's most respected growth equity firms. This strategic partnership marks an exciting new chapter in Springtime's 20-year journey of empowering enterprises with innovative solutions for financial operations.

BRANDL TALOS advises Sportradar on $ 30 million acquisition of XLMedia PLC’s North American business

Press release • Venture Capital & Start Ups from Thomas Talos, Stephan Strass

BRANDL TALOS advised its longstanding client Sportradar on the acquisition of the key assets of XLMedia PLC’s North American business.